Aquestive(US:AQST) Prnewswire·2026-02-07 15:23Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% following the FDA's identification of deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the upcoming PDUFA action date on January 31, 2026 [3]. Company Summary - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics due to the recent stock losses [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2]. Industry Context - The FDA's feedback on the New Drug Application for Anaphylm indicates significant regulatory hurdles that could impact the company's future product approvals and market performance [3].